The Phase 2b COPERNICUS Study of Subcutaneous Amivantamab with Lazertinib as First-Line Treatment, or with Chemotherapy as Second-Line Treatment, for EGFR-Mutated Non-Small Cell Lung Cancer: a Vodcast Dr. Balazs Halmos and Dr. Melissa Johnson present the phase 2b COPERNICUS study evaluating subcutaneous amivantamab, with lazertinib as first-line treatment, or with chemotherapy as second-line treatment for EGFR-mutated non-small cell lung cancer.The intent of this vodcast is to review the study design for COPERNICUS, highlighting how it combines pragmatic elements to assess the efficacy and safety of subcutaneous amivantamab with supportive care for prevention and management of adverse events in a diverse participant population. This vodcast is published open access in Oncology and Therapy and is fully citeable. You can access the original published podcast article through the Oncology and Therapy website and by using this link: https://link.springer.com/article/10.1007/s40487-025-00386-8. All conflicts of interest can be found online. This podcast is intended for medical professionals. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.